Industry

New Results Position ALZ-801 to Potentially Become the First Oral Agent that Can Slow or Even Stop and Prevent Alzheimer’s Pathology in Patients and Healthy Individuals at Risk for the Disease Several-Fold Greater Reduction on P-tau181 Compared to Anti-Amyloid Antibodies Validates Superior Clinical Benefit from Prior Studies in Alzheimer’s Patients Significant Improvement on Memory Tests … [Read more…]

BURLINGTON, Ontario–(BUSINESS WIRE)–$ELMT—Element Nutritional Sciences Inc. (CSE:ELMT; OTC:ELNSF; FRANKFURT:93X) (the “Company” or “Element”), is pleased to announce that it has completed commercialization for its Clinical Strength Rejuvenate™ formulation. The 15-gram drink mix is backed by two U.S. patents and is clinically proven to speed recovery after surgery as well as prevent muscle loss during bed … [Read more…]

NASHVILLE, Tenn.–(BUSINESS WIRE)–Six HealthTrust member organizations have been singled out for supply chain excellence, sustainability and innovation benefitting their patients, communities and stakeholders. Recipients of the annual Member Recognition Awards – the most prestigious honors presented by HealthTrust Performance Group – were announced last evening at HealthTrust University conference in Nashville. David Osborn, Ph.D., senior … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Database of Hospitals in Europe” database has been added to ResearchAndMarkets.com’s offering. The Database of Hospitals in Europe is an Excel spreadsheet containing a list of the largest 6000 Hospitals in Europe. Each of our company lists displays the leading companies ranked by revenue in $USm. Each Excel file contains the following: Company … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Checkpoint Inhibitors Global Market Report 2022: By Drug, By Application, By End-Users” report has been added to ResearchAndMarkets.com’s offering. Checkpoint Inhibitors Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global checkpoint inhibitors market. This report focuses on checkpoint inhibitors market which … [Read more…]

The new London store offers advancements in sustainable design, community events and resources, and a team of more than 200 ready to provide excellent service for customers LONDON–(BUSINESS WIRE)–Apple® today previewed Apple Brompton Road, its newest store in London, located in the city’s bustling Knightsbridge neighborhood. A stone’s throw from Hyde Park, Apple Brompton Road … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Taste Masking and Taste Assessment Services and Technologies Market, Distribution by Type of Formulation, Type of Techniques, Scale of Operation and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering. ‘Taste Masking and Taste Assessment Services and Technologies Market, 2022-2035 report features an extensive study of … [Read more…]

SINGAPORE–(BUSINESS WIRE)–#HD204—Prestige Biopharma Limited (KRX: 950210, hereafter referred to as “Prestige”) and Intas Pharmaceuticals Limited (hereafter referred to as “Intas”) today announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige Biopharma’s bevacizumab biosimilar, in the US, Europe, Canada, MENA, Brazil, Mexico, South … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Acquired von Willebrand Disease (AvWD) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030” report has been added to ResearchAndMarkets.com’s offering. The acquired von willebrand disease treatment market is anticipated to grow, at a CAGR of 5.86% during the forecast period of … [Read more…]

– Companies plan to discuss results with regulatory authorities – BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K evaluating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck’s … [Read more…]